

Michel J Grothe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8426363/publications.pdf>

Version: 2024-02-01

151
papers

6,671
citations

66343

42
h-index

76900

74
g-index

165
all docs

165
docs citations

165
times ranked

8065
citing authors

#	ARTICLE	IF	CITATIONS
1	ADCoC: Adaptive Distribution Modeling Based Collaborative Clustering for Disentangling Disease Heterogeneity from Neuroimaging Data. IEEE Transactions on Emerging Topics in Computational Intelligence, 2023, 7, 308-318.	4.9	1
2	Cholinergic basal forebrain and hippocampal structure influence visuospatial memory in Parkinson's disease. Brain Imaging and Behavior, 2022, 16, 118-129.	2.1	7
3	Brain FDG PET for Short- to Medium-Term Prediction of Further Cognitive Decline and Need for Assisted Living in Acutely Hospitalized Geriatric Patients With Newly Detected Clinically Uncertain Cognitive Impairment. Clinical Nuclear Medicine, 2022, 47, 123-129.	1.3	2
4	Age and Anterior Basal Forebrain Volume Predict the Cholinergic Deficit in Patients with Mild Cognitive Impairment due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-16.	2.6	3
5	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. Journal of the Neurological Sciences, 2022, 434, 120148.	0.6	13
6	Antemortem basal forebrain atrophy in pure limbic TAR DNA-binding protein 43 pathology compared with pure Alzheimer pathology. European Journal of Neurology, 2022, 29, 1394-1401.	3.3	3
7	CSF biomarkers and plasma τ 181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimer's and Dementia, 2022, 18, 2614-2626.	0.8	22
8	Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson's Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy. Frontiers in Aging Neuroscience, 2022, 14, 851788.	3.4	7
9	Association of β -Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. Neurology, 2022, 98, .	1.1	10
10	Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	9
11	Effective connectivity in the default mode network is distinctively disrupted in Alzheimer's disease: A simultaneous resting-state FDG-PET/fMRI study. Human Brain Mapping, 2021, 42, 4134-4143.	3.6	43
12	Metabolic and amyloid PET network reorganization in Alzheimer's disease: differential patterns and partial volume effects. Brain Imaging and Behavior, 2021, 15, 190-204.	2.1	11
13	The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
14	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Brain, 2021, 144, 325-339.	7.6	124
15	Association of TDP-43 Pathology with Global and Regional 18F-Florbetapir PET Signal in the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2021, 79, 663-670.	2.6	4
16	Association of PET-based stages of amyloid deposition with neuropathological markers of β pathology. Annals of Clinical and Translational Neurology, 2021, 8, 29-42.	3.7	7
17	Structural MRI of the basal forebrain as predictor of cognitive response to galantamine in healthy older adults: A randomized controlled double-blind crossover study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12153.	3.7	4
18	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. NeuroImage: Clinical, 2021, 30, 102660.	2.7	13

#	ARTICLE	IF	CITATIONS
19	Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2283-2294.	6.4	9
20	Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 49.	6.2	44
21	Differential associations of APOE- ϵ 2 and APOE- ϵ 4 alleles with PET-measured amyloid- β 2 and tau deposition in older individuals without dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2212-2224.	6.4	29
22	Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum. <i>Clinical Nuclear Medicine</i> , 2021, 46, e296-e306.	1.3	2
23	Four distinct trajectories of tau deposition identified in Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 871-881.	30.7	354
24	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	9.0	146
25	Aberrant Claustrum Microstructure in Humans after Premature Birth. <i>Cerebral Cortex</i> , 2021, 31, 5549-5559.	2.9	4
26	Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia. <i>Neuropsychopharmacology</i> , 2021, 46, 2320-2329.	5.4	17
27	In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 68-75.	2.2	16
28	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021, 97, .	1.1	50
29	The relationship between cholinergic system brain structure and function in healthy adults and patients with mild cognitive impairment. <i>Scientific Reports</i> , 2021, 11, 16080.	3.3	12
30	FEOBV-PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry. <i>Journal of Neuroimaging</i> , 2021, 31, 1077-1081.	2.0	7
31	In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 178.	6.2	6
32	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 748198.	3.4	3
33	Tau pathology progression across PET-based stages of regional amyloid deposition. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
34	Disentangling disease heterogeneity from neuroimaging data via adaptive distribution modeling-based collaborative clustering. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
35	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
36	Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
37	Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
38	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020, 94, e30-e41.	1.1	20
39	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020, 90, 43-59.	3.1	30
40	Disentangling Heterogeneity in Alzheimer's Disease and Related Dementias Using Data-Driven Methods. <i>Biological Psychiatry</i> , 2020, 88, 70-82.	1.3	87
41	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2020, 28, 102495.	2.7	17
42	Disentangling neurodegeneration subtypes of Alzheimer's disease using data-driven methods. <i>Alzheimer's and Dementia</i> , 2020, 16, e037183.	0.8	0
43	Clinical and neurodegenerative features associated with amyloid β -negative medial temporal tau deposition as measured by multimodal PET imaging. <i>Alzheimer's and Dementia</i> , 2020, 16, e040033.	0.8	0
44	Differential effects of APOE2 and APOE4 alleles on PET-measured amyloid β and tau deposition in older individuals without dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e040440.	0.8	1
45	Accounting for systematic spatiotemporal variation improves connectome-based models of tau spreading in human Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040586.	0.8	0
46	In vivo amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040789.	0.8	0
47	FDG-PET subtypes of Alzheimer's disease and their association with distinct biomarker profiles and clinical trajectories. <i>Alzheimer's and Dementia</i> , 2020, 16, e042101.	0.8	3
48	Magnetic resonance imaging subtypes in subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e042439.	0.8	1
49	Comparison of subtyping methods for neuroimaging studies in Alzheimer's disease: a call for harmonization. <i>Brain Communications</i> , 2020, 2, fcaa192.	3.3	24
50	Impairment of Everyday Spatial Navigation Abilities in Mild Cognitive Impairment Is Weakly Associated with Reduced Grey Matter Volume in the Medial Part of the Entorhinal Cortex. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1149-1159.	2.6	5
51	Gaussian Graphical Models Reveal Inter-Modal and Inter-Regional Conditional Dependencies of Brain Alterations in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 99.	3.4	31
52	The cholinergic system in subtypes of Alzheimer's disease: an in vivo longitudinal MRI study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 51.	6.2	41
53	Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1199-1207.	3.9	29
54	In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 93, 98-108.	3.1	21

#	ARTICLE	IF	CITATIONS
55	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 139, 104831.	4.4	49
56	Longitudinal validity of β -PET-based staging of regional amyloid deposition. <i>Human Brain Mapping</i> , 2020, 41, 4219-4231.	3.6	25
57	FDG Uptake in the Basal Forebrain as Measured by Digital High-Resolution PET Is a Promising Marker of Basal Forebrain Degeneration in the Lewy Body Disease Spectrum. <i>Clinical Nuclear Medicine</i> , 2020, 45, 261-266.	1.3	6
58	Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease. <i>Neurology</i> , 2020, 95, e1301-e1311.	1.1	29
59	Cholinergic white matter pathways make a stronger contribution to attention and memory in normal aging than cerebrovascular health and nucleus basalis of Meynert. <i>NeuroImage</i> , 2020, 211, 116607.	4.2	59
60	A molecular gradient along the longitudinal axis of the human hippocampus informs large-scale behavioral systems. <i>Nature Communications</i> , 2020, 11, 960.	12.8	100
61	Reshaping the Amyloid Buildup Curve in Alzheimer Disease? Partial-Volume Effect Correction of Longitudinal Amyloid PET Data. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1820-1824.	5.0	7
62	Connectomics and molecular imaging in neurodegeneration. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2819-2830.	6.4	21
63	Characterizing the Molecular Architecture of Cortical Regions Associated with High Educational Attainment in Older Individuals. <i>Journal of Neuroscience</i> , 2019, 39, 4566-4575.	3.6	18
64	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 15.	6.2	24
65	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid- β^2 Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. <i>Radiology</i> , 2019, 290, 167-176.	7.3	30
66	The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles. <i>Human Brain Mapping</i> , 2019, 40, 868-878.	3.6	47
67	Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD). <i>NeuroImage: Clinical</i> , 2019, 21, 101612.	2.7	35
68	Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1417-1422.	6.4	15
69	Magnetic resonance imaging-based hippocampus volume for prediction of dementia in mild cognitive impairment: Why does the measurement method matter so little?. <i>Alzheimer's and Dementia</i> , 2018, 14, 976-978.	0.8	4
70	Hypermetabolism in the hippocampal formation of cognitively impaired patients indicates detrimental maladaptation. <i>Neurobiology of Aging</i> , 2018, 65, 41-50.	3.1	21
71	Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia. <i>Current Geriatrics Reports</i> , 2018, 7, 1-11.	1.1	75
72	In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease. <i>Brain</i> , 2018, 141, 165-176.	7.6	135

#	ARTICLE	IF	CITATIONS
73	Mean diffusivity in cortical gray matter in Alzheimer's disease: The importance of partial volume correction. <i>NeuroImage: Clinical</i> , 2018, 17, 579-586.	2.7	40
74	No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. <i>NeuroImage: Clinical</i> , 2018, 17, 435-443.	2.7	19
75	Comparison of Different Hypotheses Regarding the Spread of Alzheimer's Disease Using Markov Random Fields and Multimodal Imaging. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 731-746.	2.6	6
76	6 .Diagnostische Methoden. , 2018, , 187-352.		0
77	Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. <i>Nature Medicine</i> , 2018, 24, 1910-1918.	30.7	135
78	Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors. <i>Frontiers in Neurology</i> , 2018, 9, 642.	2.4	32
79	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-AD study. <i>Alzheimer's and Dementia</i> , 2018, 14, 1126-1136.	0.8	20
80	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018, 14, 1204-1215.	0.8	79
81	Molecular properties underlying regional vulnerability to Alzheimer's disease pathology. <i>Brain</i> , 2018, 141, 2755-2771.	7.6	89
82	In Vivo Volumetry of the Cholinergic Basal Forebrain. <i>NeuroMethods</i> , 2018, , 213-232.	0.3	5
83	The European DTI Study on Dementia – A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. <i>NeuroImage</i> , 2017, 144, 305-308.	4.2	33
84	Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. <i>Neurology</i> , 2017, 88, 569-576.	1.1	50
85	Multicenter stability of resting state fMRI in the detection of Alzheimer's disease and amnesic MCI. <i>NeuroImage: Clinical</i> , 2017, 14, 183-194.	2.7	49
86	Individual Correspondence of Amyloid- β^2 and Intrinsic Connectivity in the Posterior Default Mode Network Across Stages of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 763-773.	2.6	30
87	Basal forebrain mediated increase in brain CRF is associated with increased cholinergic tone and depression. <i>Psychiatry Research - Neuroimaging</i> , 2017, 264, 76-81.	1.8	0
88	Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. <i>JAMA Neurology</i> , 2017, 74, 813.	9.0	61
89	Reference standard space hippocampus labels according to the European Alzheimer's Disease Consortium's Alzheimer's Disease Neuroimaging Initiative harmonized protocol: Utility in automated volumetry. <i>Alzheimer's and Dementia</i> , 2017, 13, 893-902.	0.8	32
90	PETPVE12: an SPM toolbox for Partial Volume Effects correction in brain PET – Application to amyloid imaging with AV45-PET. <i>NeuroImage</i> , 2017, 147, 669-677.	4.2	134

#	ARTICLE	IF	CITATIONS
91	Reduced Cholinergic Basal Forebrain Integrity Links Neonatal Complications and Adult Cognitive Deficits After Premature Birth. <i>Biological Psychiatry</i> , 2017, 82, 119-126.	1.3	30
92	In vivo staging of regional amyloid deposition. <i>Neurology</i> , 2017, 89, 2031-2038.	1.1	321
93	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 11706.	3.3	79
94	[P3â€“350]: GLOBAL TAU BURDEN CORRELATES WITH BASAL FOREBRAIN ATROPHY IN HEALTHY AGING SUBJECTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1089.	0.8	0
95	[ICâ€“Pâ€“18]: GLOBAL TAU BURDEN CORRELATES WITH BASAL FOREBRAIN ATROPHY IN HEALTHY AGING SUBJECTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P91.	0.8	0
96	[ICâ€“Pâ€“152]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTINGâ€“STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€“PRE AD STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P114.	0.8	0
97	[P1â€“441]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTINGâ€“STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€“PREâ€“AD STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P451.	0.8	0
98	[F4â€“01â€“03]: HETEROGENEITY OF HYPOMETABOLIC BRAIN DYSFUNCTION IN AMNESTIC MCI. <i>Alzheimer's and Dementia</i> , 2017, 13, P1211.	0.8	0
99	Does Functional Connectivity Provide a Marker for Cognitive Rehabilitation Effects in Alzheimer's Disease? An Interventional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1303-1313.	2.6	12
100	Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. <i>Frontiers in Neuroscience</i> , 2017, 11, 167.	2.8	87
101	Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. <i>Neurobiology of Aging</i> , 2017, 57, 143-152.	3.1	18
102	Contribution of the Cholinergic System to Verbal Memory Performance in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 991-1001.	2.6	26
103	Association Between Smoking and Cholinergic Basal Forebrain Volume in Healthy Aging and Prodromal and Dementia Stages of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1443-1451.	2.6	13
104	IC-P-045: Functional Connectivity in Alzheimer's Dementia and Mild Cognitive Impairment: A Large-Scale Multicenter Resting-State fMRI Study. , 2016, 12, P38-P38.		0
105	Measuring Cortical Connectivity in Alzheimer's Disease as a Brain Neural Network Pathology: Toward Clinical Applications. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 138-163.	1.8	92
106	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. <i>Cortex</i> , 2016, 83, 124-135.	2.4	21
107	Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer's disease correspond to dissociable functional brain networks. <i>Human Brain Mapping</i> , 2016, 37, 35-53.	3.6	119
108	Hippocampal volume and integrity as predictors of cognitive decline in intact elderly. <i>NeuroReport</i> , 2016, 27, 869-873.	1.2	10

#	ARTICLE	IF	CITATIONS
109	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. <i>Neuropharmacology</i> , 2016, 108, 128-135.	4.1	23
110	Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 526-536.	6.4	58
111	Output order and variability in free recall are linked to cognitive ability and hippocampal volume in elderly individuals. <i>Neuropsychologia</i> , 2016, 80, 126-132.	1.6	9
112	Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment. <i>Cerebral Cortex</i> , 2016, 26, 2411-2426.	2.9	81
113	Robust Detection of Impaired Resting State Functional Connectivity Networks in Alzheimer's Disease Using Elastic Net Regularized Regression. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 318.	3.4	36
114	Neuronal correlates of serial position performance in amnesic mild cognitive impairment.. <i>Neuropsychology</i> , 2016, 30, 906-914.	1.3	15
115	Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment – A Multicenter DTI and Volumetry Study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 197-204.	2.6	56
116	P3-179: A comparison of hippocampal volume and integrity: Which is the better predictor of cognitive decline?. , 2015, 11, P698-P699.		0
117	O2-10-03: In vivo characterization of basal forebrain atrophy and cholinergic denervation in primary progressive aphasia. , 2015, 11, P198-P198.		0
118	Multimodal analysis of functional and structural disconnection in Alzheimer's disease using multiple kernel SVM. <i>Human Brain Mapping</i> , 2015, 36, 2118-2131.	3.6	156
119	A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. <i>Neuropsychologia</i> , 2015, 69, 1-8.	1.6	25
120	Cholinergic Basal Forebrain Structure Influences the Reconfiguration of White Matter Connections to Support Residual Memory in Mild Cognitive Impairment. <i>Journal of Neuroscience</i> , 2015, 35, 739-747.	3.6	45
121	Training labels for hippocampal segmentation based on the EADC-ADNI harmonized hippocampal protocol. <i>Alzheimer's and Dementia</i> , 2015, 11, 175-183.	0.8	105
122	The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. <i>Alzheimer's and Dementia</i> , 2015, 11, 111-125.	0.8	162
123	The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment – Beyond classical regression. <i>NeuroImage: Clinical</i> , 2015, 8, 583-593.	2.7	77
124	Association of a neurokinin 3 receptor polymorphism with the anterior basal forebrain. <i>Neurobiology of Aging</i> , 2015, 36, 2060-2067.	3.1	9
125	The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 81-86.	2.4	7
126	Hippocampus and basal forebrain volumes modulate effects of anticholinergic treatment on delayed recall in healthy older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 216-219.	2.4	4

#	ARTICLE	IF	CITATIONS
127	Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. <i>Lancet Neurology</i> , The, 2015, 14, 1037-1053.	10.2	233
128	The complex link between amyloid and neuronal dysfunction in Alzheimer's disease. <i>Brain</i> , 2015, 138, 3472-3475.	7.6	14
129	Building bridges: experiences and lessons learned from the implementation of INSPIRE and e-reporting of air quality data in Europe. <i>Earth Science Informatics</i> , 2015, 8, 353-365.	3.2	12
130	Decline of fiber tract integrity over the adult age range: A diffusion spectrum imaging study. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 348-359.	3.4	9
131	Distinct pattern of hypometabolism and atrophy in preclinical and prodementia Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1973-1981.	3.1	52
132	Brain atrophy in primary progressive aphasia involves the cholinergic basal forebrain and Ayla's nucleus. <i>Psychiatry Research - Neuroimaging</i> , 2014, 221, 187-194.	1.8	25
133	Subregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 687-700.	2.6	173
134	Standardization of MRI and Amyloid Imaging. , 2014, , 131-156.		2
135	Functional and Structural MRI in Alzheimer's Disease: A Multimodal Approach. , 2014, , 371-422.		0
136	Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia. <i>Journal of Neurology</i> , 2014, 261, 1939-1948.	3.6	113
137	Fractional Anisotropy Changes in Alzheimer's Disease Depend on the Underlying Fiber Tract Architecture: A Multiparametric DTI Study using Joint Independent Component Analysis. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 69-83.	2.6	71
138	Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. <i>Alzheimer's and Dementia</i> , 2014, 10, S344-53.	0.8	79
139	Association of basal forebrain volumes and cognition in normal aging. <i>Neuropsychologia</i> , 2014, 53, 54-63.	1.6	39
140	Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 482-491.	3.1	94
141	Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 1210-1220.	3.1	169
142	Relevance of Magnetic Resonance Imaging for Early Detection and Diagnosis of Alzheimer Disease. <i>Medical Clinics of North America</i> , 2013, 97, 399-424.	2.5	151
143	Brain volumes differ between diagnostic groups of violent criminal offenders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 593-606.	3.2	80
144	Convergent Findings of Altered Functional and Structural Brain Connectivity in Individuals with High Functioning Autism: A Multimodal MRI Study. <i>PLoS ONE</i> , 2013, 8, e67329.	2.5	132

#	ARTICLE	IF	CITATIONS
145	Atrophy of the Cholinergic Basal Forebrain Over the Adult Age Range and in Early Stages of Alzheimer's Disease. <i>Biological Psychiatry</i> , 2012, 71, 805-813.	1.3	254
146	Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S329-S347.	2.6	21
147	The cholinergic system in mild cognitive impairment and Alzheimer's disease: An in vivo MRI and DTI study. <i>Human Brain Mapping</i> , 2011, 32, 1349-1362.	3.6	136
148	Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 109-113.	2.6	8
149	The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. <i>Psychiatry Research - Neuroimaging</i> , 2010, 183, 44-51.	1.8	26
150	A novel MRI biomarker candidate for Alzheimer's disease composed of regional brain volume and perfusion variables. <i>European Journal of Neurology</i> , 2010, 17, 1437-1444.	3.3	13
151	Reduction of Basal Forebrain Cholinergic System Parallels Cognitive Impairment in Patients at High Risk of Developing Alzheimer's Disease. <i>Cerebral Cortex</i> , 2010, 20, 1685-1695.	2.9	183